YOLFTbeta
Edgewise Therapeutics Inc

Edgewise Therapeutics Inc

EWTX · NASDAQ · Healthcare / Biotechnology

45.93USD+0.11 (+0.24%)

Price History

Full chart

Market Stats

Previous Close45.82
Open45.72
Day Range44.08 – 46.75
52-Week Range14.25 – 48.51
Volume1.15M
Market Cap4.47B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.86
Dividend Yield0.00%
Beta0.33
50-Day Avg42.73
200-Day Avg34.22

About

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Kevin Koch Ph.D.
  • Employees127
  • Headquarters1715 38th Street, Boulder, CO, United States, 80301, USA
  • Websitehttps://edgewisetx.com

Leadership

  • Dr. Peter A. Thompson FACP, M.D.Co-Founder & Independent Chairman · b. 1960
  • Dr. Kevin Koch Ph.D.President, CEO & Director · b. 1960
  • Dr. Badreddin Edris Ph.D.Co-Founder & Independent Director · b. 1987
  • Dr. Alan J. Russell Ph.D.Co-Founder, Chief Scientific Officer & Director · b. 1970
  • Mr. Michael P. NofiChief Financial Officer · b. 1971
  • Dr. Behrad Derakhshan Ph.D.Chief Operating Officer · b. 1980
  • Dr. Joanne M. Donovan M.D., Ph.D.Chief Medical Officer · b. 1957
  • Mr. John R. Moore J.D.General Counsel · b. 1964
  • Dr. Aylin TugcuSenior Vice President of Cardiovascular Clinical Development & Medical Affairs

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue123.00K185.00K272.00K538.00K1.73M2.29M2.27M
Gross Profit-123.00K-185.00K-272.00K-538.00K-1.73M-2.29M-2.27M
Operating Expense9.80M17.01M42.94M21.54M112.63M156.54M189.14M
Operating Income-9.92M-17.19M-43.22M-22.08M-114.36M-158.83M-191.41M
EBITDA-9.80M-17.01M-42.94M-21.54M-98.43M-131.52M-165.53M
Net Income-9.49M-17.05M-42.14M-15.40M-100.16M-133.81M-167.79M
R&D8.62M14.80M32.19M16.61M90.91M126.97M151.39M
Interest Expense069.00K272.00K4.02M---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.54M131.14M285.23M367.10M340.04M486.82M552.60M
Total Liabilities41.39M164.56M10.85M20.39M21.20M27.60M30.35M
Total Equity-16.85M-33.42M274.38M346.72M318.83M459.22M522.26M
Cash23.65M104.92M15.57M21.99M86.10M41.67M61.15M
Total Debt40.26M160.21M-4.41M5.41M4.74M3.99M
Net Debt-23.65M55.30M-15.57M-17.59M-80.68M-36.93M-57.16M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-9.17M-14.63M-33.51M-52.63M-91.95M-109.03M-143.82M
Investing Cash Flow-180.00K-24.38M-242.23M-70.58M102.89M-184.66M-32.79M
Financing Cash Flow24.80M120.28M186.38M129.64M53.17M249.25M196.09M
Capital Expenditure180.00K203.00K668.00K5.55M5.75M1.31M256.00K
Free Cash Flow-9.35M-14.84M-34.17M-58.18M-97.69M-110.34M-143.82M
FCF to OCF101.96%101.39%101.99%110.54%106.25%101.20%100.00%

Earnings

Report DateMar 26, 2021May 13, 2021Aug 9, 2021Nov 10, 2021Feb 24, 2022May 11, 2022Aug 4, 2022Nov 3, 2022Feb 23, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Feb 22, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Feb 20, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.00-0.15-0.17-0.24-0.25-0.28-0.32-0.36-0.33-0.35-0.40-0.40-0.43-0.41-0.34-0.37-0.42-0.42-0.42-0.40-0.43-0.48-0.48-0.55
EPS Actual0.00-0.14-0.21-0.26-0.26-0.30-0.32-0.34-0.31-0.36-0.34-0.41-0.47-0.33-0.34-0.36-0.42-0.43-0.34-0.39-0.47-0.46-0.53-
Surprise-6.67%-23.53%-8.33%-4.00%-7.14%0.00%5.56%6.06%-2.86%15.00%-2.50%-9.30%19.51%0.00%2.70%0.52%-2.38%19.05%2.50%-9.30%4.17%-10.42%-
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap4.47B
Enterprise Value4.00B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book9.95
EPS-1.86
Book Value4.16
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-216.77M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-38.03%
Return on Assets-25.03%
Shares Outstanding108.60M
Shares Float74.26M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 10 analystsTarget 52.62
  • Strong Buy
    5
  • Buy
    3
  • Hold
    2

Ownership Breakdown

Institutions
111.68%
Insiders
0.49%
Retail / Other
0.00%

Top Institutional Holders

  • Orbimed Advisors LLC
    15.52M14.29%
  • RA Capital Management, LLC
    10.43M9.60%
  • Paradigm Biocapital Advisors LP
    10.22M9.41%
  • Baker Bros Advisors LP
    6.58M6.05%
  • BlackRock Inc
    6.47M5.96%
  • HHG PLC
    5.92M5.45%
  • Novo A/S
    5.35M4.93%
  • Driehaus Capital Management LLC
    4.48M4.12%
  • Siren, L.L.C.
    4.43M4.08%
  • Perceptive Advisors LLC
    4.37M4.03%
  • Vanguard Capital Management, LLC
    3.79M3.49%
  • Cormorant Asset Management, LLC
    3.26M3.00%
  • BRAIDWELL LP
    2.35M2.16%
  • Morgan Stanley - Brokerage Accounts
    2.25M2.07%
  • Integral Health Asset Management, LLC
    2.00M1.84%
  • Geode Capital Management, LLC
    1.79M1.65%
  • AllianceBernstein L.P.
    1.72M1.59%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.91M2.68%
  • Strategic Advisers Fidelity US TtlStk
    2.81M2.59%
  • iShares Russell 2000 ETF
    1.82M1.68%